Surgical Outcomes in Gastric Cancer

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

The enormous influence of the surgeon on outlook in cancer was stressed by Professor Cornelis van de Velde of the Department of Surgery, Leiden University Medical Center, the Netherlands, during the 1997 European Cancer Conference.

The enormous influence of the surgeon on outlook in cancer was stressed by Professor Cornelis van de Velde of the Department of Surgery, Leiden University Medical Center, the Netherlands, during the 1997 European Cancer Conference.

“Quality of surgery can make the most tremendous difference to your chances of survival and the quality of a patient’s remaining life,” said Professor van de Velde. “In rectal cancer, for example, the local recurrence rate can vary enormously between surgeons, from 5% to 50% or 60%, and this can affect not only your risk of dying of metastases, but the degree of suffering. Many local recurrences in rectal cancer are untreatable and cause immense and unbearable symptoms.”

“Survival rates in gastric and rectal cancer can vary as much as 5% to 10% between different surgeons, more than the effect gained from adjuvant treatment.” Professor van de Velde continued. “Morbidity, mortality and survival vary substantially between surgeons. Also more extensive surgery does not necessarily improve survival, so addressing the issues about individual surgical performance is a major issue.” 

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content